BRCA1/2-mutated patients with secondary platinum-sensitive relapse included in this study... Of note, 26 patients in control group were treated with PARPi...the results showed that both PARPi monotherapy after secondary platinum-sensitive relapse (Fig. 3, median PRS: 41.2 vs. 33.7 months, p=0.019) and post-line treatment with PARPi (Fig. 3, median PRS: 48.1 vs. 33.7 months, p=0.002) prolonged PRS in patients compared to those who had never used PARPi.